Investors Urged to Act: Legal Deadline Approaches for BioAge Labs Class Action

Important Deadline for Investors

Glancy Prongay & Murray LLP is reminding investors that the deadline to file a lead plaintiff motion in a class action lawsuit against BioAge Labs, Inc. (“BioAge” or the “Company”) is March 10, 2025. This action affects those who bought or acquired BioAge’s common stock, identified by ticker BIOA, based on claims in the Registration Statement from the Company’s September 2024 initial public offering (IPO).

If you experienced a loss from your BioAge investment, click here to explore your options for recovering losses under federal securities laws.

Background of the Situation

BioAge conducted its IPO around September 2024, raising funds by selling 12.65 million shares at a price of $18 each.

However, on December 6, 2024, the Company announced it was halting its STRIDES Phase 2 study for the drug candidate azelaprag after liver transaminitis was reported in certain participants.

Following this news, BioAge’s stock experienced a sharp drop, plummeting $15.44 or 76.85%, finishing at $4.65 per share on December 9, 2024.

Currently, BioAge’s stock is trading at $5.82 per share, reflecting a decrease of over 67% from its initial IPO price.

Overview of the Lawsuit

The class action lawsuit alleges that the defendants made significant misstatements and failed to reveal critical information regarding BioAge’s business operations and prospects. Key claims include:

• The potential for liver transaminitis was not disclosed during previous Phase 1 trials or preclinical studies.
• Safety concerns regarding the ongoing STRIDES study were not fully communicated to investors.
• The likelihood of completing the ongoing STRIDES study was exaggerated.
• The expectations for a second Phase 2 trial involving azelaprag and semaglutide were overstated.
• The defendants’ positive remarks about BioAge lacked a reasonable basis at all relevant times.

Investors who acquired BioAge securities during the Class Period may file a motion to be appointed as lead plaintiff by the March 10, 2025 deadline.

Learn How to Get Involved

For more information about this case or if you have questions about your rights regarding this matter, please reach out:

Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224.
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you email, please include your mailing address, phone number, and the number of shares purchased.

Taking part in the class action does not require immediate action; you can choose to have your own lawyer or opt to remain an absent class member.

This announcement may be regarded as Attorney Advertising in certain jurisdictions.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115181235/en/

Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.